Table 3.

Overview on existing pharmacological intervention studies. For the interpretation of parameters reported in columns “Modelling: Outcome”, “Predictor”, and “Significant prediction results”, please see Table 1

Study	Modelling Outcome	#Participants (per group)	Experimental design	Predictor	Pred. meth	Significant prediction results
Task-fMRI
Ten Kulve et al. [86]	Prognostic: Bodyweight	20 OW/OB: Liraglutide (vs. Insulin; cross-over design)	T0 (before treatment), T0.3 (after 10 days of treatment), T3 (after 12 weeks of treatment)	Voxel CR activity	OLS	CR_fMRI_T0.3_3 → OUT_T0_12: No association between WL and evaluated neuroimaging predictors was found
Ten Kulve et al. [199]	Prognostic: Bodyweight	20 OW/OB: Liraglutide (vs. Insulin; cross-over design)	T0 (before treatment), T0.3 (after 10 days of treatment), T3 (after 12 weeks of treatment)	Voxel CR activity	OLS	CR_fMRI_T0.3 → OUT_T0_12: Positive association between WL and higher CR activity in right insula after liraglutide vs. after insulin

CR cue reactivity, fMRI functional magnetic resonance imaging, OB obese, OLS ordinary least square regression, OUT outcome marker, OW overweight, Pred. meth computational prediction method, WL weight loss